AGL28 Antibody
Description
Context of AGL28 in Autoantibody Research
The designation "AGL28" refers to a patient code in a clinical cohort study investigating anti-PLIN1 autoantibodies in AGL (Table 2, ). AGL28 was classified under the autoimmune variety of lipodystrophy and exhibited IgG-type autoantibodies with the following characteristics:
-
IgG subclass: IgG3
-
Light chains: κ + λ
-
IgG autoantibody titer: 421.4 AU/mL
This patient’s serum showed reactivity against the PLIN1 epitope 383–403, a key region recognized by anti-PLIN1 autoantibodies in AGL .
2.1. Diagnostic and Pathogenic Role
-
Anti-PLIN1 autoantibodies are a diagnostic biomarker for AGL, particularly in autoimmune and panniculitis-associated subtypes .
-
These autoantibodies target intracellular lipid-droplet proteins, leading to adipocyte destruction and systemic metabolic dysfunction.
Comparative Analysis of AGL Patient Data
Data from the AGL cohort (n=20) revealed the following patterns for anti-PLIN1 autoantibodies :
| Parameter | IgG-Positive Patients (n=19) | IgM-Positive Patients (n=6) |
|---|---|---|
| Median disease duration | 13.43 years | 8.82 years |
| Fat mass reduction | 75% exhibited reduced adiposity | 66.7% exhibited reduced adiposity |
| Light chain usage | 75% κ + λ; 25% κ-only | 100% κ + λ |
Therapeutic Implications
While AGL28 itself is not a therapeutic antibody, the study highlights:
-
Clinical relevance: Anti-PLIN1 autoantibodies correlate with metabolic complications such as hypertriglyceridemia and diabetes .
-
Treatment gaps: No targeted therapies exist for AGL; management focuses on metabolic symptom relief (e.g., leptin replacement) .
Research Limitations and Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- AGL28 plays a role in the vegetative phase of Arabidopsis and serves as a positive regulator of known floral promoters within the autonomous pathway. [AGAMOUS-LIKE 28] [AGL28] PMID: 16899218
